Abstract 2703
Background
Uveal melanoma (UM) is a rare cancer that arises from melanocytes in the uveal tract of the eye. Despite effective treatment for primary UM, > 50% of patients develop metastatic disease. There is currently no effective treatment for metastatic UM and median life expectancy is < 8 months. About 90% of UM are characterised by mutations in the GNAQ or GNA11 GTPases and several signalling cascades downstream of G-protein activation have been identified as potentially targetable. These include the protein kinase C (PKC), mitogen activated protein kinase (MAPK), phosphatidylinositol-3-kinases (PI3K), mammalian target of rapamycin (mTOR), and YES-associated protein (YAP) pathways. Aim to understand the relative contribution of oncogenic signaling pathways in proliferation and survival of UM.
Methods
The response 11 UM cell lines to 6 selective inhibitors was investigated using cell viability assays and cell cycle analyses by flow cytometry. Inhibition of selected pathways was examined using Western analysis of downstream effector proteins. The inhibitors used in this study included PKC inhibitors (AEB071 and LXS196), MEK inhibitor (trametinib), PI3K/mTOR inhibitor (BEZ235), YAP inhibitor (verteporfin) and ARF6 inhibitor (NAV2729).
Results
PKC inhibitors were most effective with 8 GNAQ/11 mutant UM cell lines showing some degree of sensitivity to each of the inhibitors, although sensitivity was usually associated with proliferative arrest rather than cell death. (see Table) Expression levels of pMARCKS and pERK were strongly inhibited by PKC inhibitors, however inhibition of these effector proteins did not reflect the degree of UM cell sensitivity.Table:
21P Summary of UM cell lines to each inhibitor. Combined result of cell viability assay and cell cycle analysis
Cell Line | Mutation | Trametinib | BEZ235 | NAV2729 | AEB071 | Verteporfin | LXS196 |
---|---|---|---|---|---|---|---|
Mel270 | GNAQ | sensitive | sensitive | sensitive | sensitive | sensitive | sensitive |
OMM1 | GNA11 | resistant | sensitive | intermediate sensitivity | sensitive | sensitive | sensitive |
92.1 | GNAQ | resistant | intermediate sensitivity | sensitive | intermediate sensitivity | sensitive | intermediate sensitivity |
Mel202 | GNAQ | resistant | intermediate sensitivity | sensitive | intermediate sensitivity | sensitive | intermediate sensitivity |
OMM1.3 | GNAQ | resistant | intermediate sensitivity | resistant | intermediate sensitivity | resistant | intermediate sensitivity |
OMM1.5 | GNAQ | resistant | resistant | resistant | intermediate sensitivity | resistant | intermediate sensitivity |
MP41 | GNA11 | resistant | resistant | resistant | intermediate sensitivity | resistant | intermediate sensitivity |
MP46 | GNAQ | resistant | resistant | resistant | resistant | resistant | intermediate sensitivity |
MP38 | GNAQ | resistant | resistant | resistant | resistant | resistant | resistant |
Mel290 | Nil | resistant | intermediate sensitivity | resistant | resistant | resistant | resistant |
Mel285 | Nil | resistant | resistant | resistant | resistant | resistant | resistant |
Conclusions
The sensitivity of GNAQ/11 mutation UM cell lines to 6 targeted drugs is heterogeneous and no single dominant signalling pathway was identified. This suggest that multiple, independent signal pathways contribute to the survival of UM. Thus, inhibition of any single pathway is unlikely to be effective in the treatment of majority of metastatic UM.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4321 - Health-related quality of life of advanced melanoma survivors treated with CTLA-4 immune checkpoint inhibition: a matched cohort study
Presenter: Annelies Boekhout
Session: Poster Display session 1
Resources:
Abstract
779 - Capecitabine vs Cisplatin along with concurrent radiotherapy in the treatment of inoperable lower esophageal cancers focusing on TWISTT score and QOL
Presenter: Goutham Anugu
Session: Poster Display session 1
Resources:
Abstract
5914 - Cancer, Mental Health and End Life Simulation (CAMhELS): A novel effectiveness evaluation.
Presenter: Asanga Fernando
Session: Poster Display session 1
Resources:
Abstract
2597 - Cancer patients’ expectations and understanding about their disease
Presenter: Mónica Pinho
Session: Poster Display session 1
Resources:
Abstract
5187 - Impact of patients’ death on oncologists and coping strategies: An online survey
Presenter: Soumaya Labidi
Session: Poster Display session 1
Resources:
Abstract
4579 - Clinical benefit from late lines of therapy offered to patients treated in a tertiary referral centre
Presenter: Andrea Sbrana
Session: Poster Display session 1
Resources:
Abstract
5058 - Preparedness for caregiving in caregivers of cancer patients
Presenter: Hatice Yakar
Session: Poster Display session 1
Resources:
Abstract
5917 - Oncologic Emergency Medicine in the real world: A survey and proposal for improvement
Presenter: Carintia Dorta Pérez
Session: Poster Display session 1
Resources:
Abstract
4077 - The Reality of Critical Cancer Patients in a Polyvalent Intensive Care Unit
Presenter: Tiago Filipe Da Cruz Tomas
Session: Poster Display session 1
Resources:
Abstract
1728 - A phase III trial evaluating olanzapine 5 mg for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin: J-FORCE Study
Presenter: Hironobu Hashimoto
Session: Poster Display session 1
Resources:
Abstract